cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6073/pasta/93b47266b20bc1782c8df9c36169e372
title: SBC LTER: Time series of quarterly NetCDF files of kelp biomass in the canopy from Landsat 5, 7 and 8, since 1984 (ongoing)

description: This data file represents a time series of canopy area of giant kelp, Macrocystis pyrifera, and bull kelp, Nereocystis luetkeana, and canopy biomass of giant kelp derived from Landsat 5 Thematic Mapper (TM), Landsat 7 Enhanced Thematic Mapper Plus (ETM+), and Landsat 8 Operational Land Imager (OLI) satellite imagery, along with relevant metadata. The kelp canopy is composed of the portions of fronds and stipes floating on the surface of the water. Canopy area (m2) data are given for individual 30 x 30 meter pixels for all coastal areas of Baja California, Mexico, California, and Oregon, including offshore islands. Biomass data (wet weight, kg) are given for individual 30 x 30 meter pixels in the coastal areas extending from near Ano Nuevo, CA through the southern range limit in Baja California (including offshore islands), representing the range where giant kelp is the dominant canopy forming species. Data were derived from the three Landsat sensors listed above. Observations are made on a 16 day repeat cycle, for each instrument, but the temporal coverage is irregular because of cloud cover, instrument failure, and the mission length of each sensor (TM: 1984 – 2011, ETM+: 1999 – present, OLI: 2013 – present). Estimates of canopy area are derived from the fractional cover of kelp canopy determined from satellite surface reflectance. Estimates of kelp canopy biomass are derived from the relationship between giant kelp fractional cover determined from satellite surface reflectance and empirical measurements of giant kelp canopy biomass in long-term SBC LTER study plots obtained using SCUBA. The different Landsat sensors were calibrated to each other using simulated Landsat data derived from hyperspectral imagery. Missing data due to the ETM+ scan line corrector error were filled using a synchrony-based gap filling method. Data are organized into a single NetCDF file and contain the quarterly area and biomass means for each Landsat pixel across the three sensors. Relevant metadata such as number of Landsat estimates from which the mean was derived, the number of estimates from each sensor, standard error for each quarterly estimate, spatial coordinates, and date are all included in the file. For assistance with the data, please contact sbclter@msi.ucsb.edu.
DOI: 10.6084/m9.figshare.22811261
title: Supplementary Material for: Tissue glue-based sealing patch for the in vivo prevention of iatrogenic prelabour preterm rupture of fetal membranes (iPPROM)

description: Introduction: One of the main concerns for all fetal surgeries is the risk of preterm delivery due to the preterm prelabor rupture of the fetal membranes (iPPROM). Clinical approaches to seal fetal membrane (FM) defects are missing due to the lack of appropriate strategies to apply sealing biomaterials at the defect site. Methods: Here, we test the performance of a previously developed strategy to seal FM defects with cyanoacrylate-based sealing patches in an ovine model up to 24 days after application. Results: Patches sealed tightly the fetoscopy-induced FM defects and remained firmly attached to the defect over 10 days. At 10 days after treatment 100% (13/13) of the patches were attached to the FMs, at 24 days after treatment 25% (1/4) of the patches placed in CO2 insufflation and 33% (1/3) in NaCl infusion remained. However, all successfully applied patches (20/24) led to a watertight sealing at 10 or 24 days after treatment. Histological analysis indicated that cyanoacrylates induced a moderate immune response and induced the disruption of the FM epithelium. Discussion/Conclusion: Together, these data show the feasibility of minimally-invasive sealing of FM defects by locally gathering tissue adhesive. Further development to combine this technology with refined tissue glues or healing-inducing materials holds great promise for future clinical translation.
DOI: 10.6084/m9.figshare.24579757
title: Supplementary Material for: Treatment strategies and prognosis for moderate stroke patients in China

description: Introduction: Moderate stroke patients with National Institutes of Health Stroke Scale (NIHSS) score of 4–10 and without intravenous thrombolysis or endovascular treatment are basically excluded from current secondary prevention trials. We aimed to explore the effectiveness of mono- vs. dual-antiplatelet (DAPT) treatment strategies against subsequent stroke for these patients in a nationwide cohort.
Methods: Data were derived from the Third China National Stroke Registry (CNSR-Ш). In this prospective nationwide cohort, moderate ischemic stroke patients with NIHSS 4–10 and without intravenous thrombolysis or endovascular treatment were included and categorized into mono- or dual-antiplatelet groups. Demographics, medical history, NIHSS score, imaging and laboratory data were collected. The outcomes were stroke recurrence and all-cause mortality at 3 months and at 1 year, respectively. Cox proportional-hazards models were utilized to investigate the association of treatment strategies and prognosis.
Results: Of a total of 2 414 patients enrolled in the study, 1 633 (67.6%) received clopidogrel or aspirin and 781 (32.4%) received DAPT. Recurrent stroke occurred in 108 (6.6%) patients of the mono-antiplatelt group and 40 (5.1%) patients of the DAPT group ( adjusted hazard ratio [aHR] 0.73, 95% confidential interval [CI] 0.47-1.13, P=0.16) at 3 months, and the rate of stroke recurrence was 10.7% in the mono-antiplatelet group and 8.6% in the DAPT group ( aHR 0.81, 95% CI 0.58-1.13, P=0.22) at 12 months. The DAPT paradigm was not significantly associated with death at 3 months (0.6% vs 0.3%, a HR 0.28, 95%CI 0.04-2.25) but significantly reduced the mortality at 12 months (2.3% vs 1.0%, aHR 0.41, 95% CI 0.17-0.98, P=0.046).
Conclusions: In moderate stroke patients presenting within 24 hours of symptom onset, the addition of clopidogrel 75 mg to aspirin might not be associated with lower risk of recurrent stroke than aspirin or clopidogrel alone.
DOI: 10.6084/m9.figshare.24588762
title: Supplementary Material for: Prevalence and Prognostic Value of Atrial Cardiopathy in Embolic Stroke of Undetermined Source

description: Introduction: We utilized data from the Third China National Stroke Registry to investigate the prevalence of atrial cardiopathy markers in patients with embolic stroke of undetermined source (ESUS) and to assess their association with death and stroke recurrence. Methods: In China, patients experiencing transient ischemic attack or ischemic stroke were recruited consecutively by the Third China National Stroke Registry. We compared atrial cardiopathy markers, such as left atrial (LA) enlargement, increased P-wave terminal force in lead V1 (PTFV1), premature atrial contractions, paroxysmal supraventricular tachycardia, advanced interatrial block, prolonged PR interval, prolonged P-wave dispersion, and prolonged P-wave duration between ESUS patients and those with small vessel disease and large artery atherosclerosis strokes. The association between these markers and the recurrence of stroke as well as mortality risk in ESUS patients was evaluated using Cox regression analysis. Results: Of 8528 ischemic stroke patients who underwent a standard diagnostic work-up, 2415 were identified as having ESUS. Multivariable analysis revealed a significant association between elevated PTFV1 and an increased risk of stroke recurrence (HR: 2.50; 95% CI: 1.53-4.09; p &lt; 0.01) as well as mortality (HR: 3.76; 95% CI: 1.58-8.91; p &lt; 0.01) at 1 year in patients with ESUS. Furthermore, we observed that moderate-severe LA enlargement slightly increased the risk of stroke recurrence in patients with ESUS (HR: 1.95; 95% CI: 0.90-4.26; p = 0.09). Both LA diameter (HR: 1.03; 95% CI: 1.00-1.06; p = 0.03) and the top quartile of the LA diameter index (HR: 1.56; 95% CI: 1.03-2.40; p = 0.04) were associated with stroke recurrence in patients with ESUS. Conclusions: PTFV1 was independently associated with an elevated risk of stroke recurrence and mortality in ESUS patients. Additionally, a trend toward a correlation between LA enlargement and high stroke recurrence risk after ESUS was observed.
DOI: 10.6084/m9.figshare.24589614
title: Supplementary Material for: Association between Fibrinogen-to-Albumin Ratio and Adverse Stroke Outcomes among Patients with Acute Ischemic Stroke

description: Introduction: Fibrinogen-to-albumin ratio (FAR) is implicated in prothrombotic states and is associated with an increased risk of acute ischemic stroke (AIS). However, studies investigating whether the prothrombotic effect of FAR is associated with long-term adverse outcomes in patients with AIS are lacking. Therefore, we aimed to investigate the association based on The Third China National Stroke Registry (CNSR-III). 
Methods: Patients with AIS with complete laboratory data for fibrinogen and albumin in the CNRS-III were included in this study. The primary outcomes were poor functional outcomes (modified Rankin scale score 3–6) at 12 months, including disability (modified Rankin scale score 3–5), all-cause death, recurrent stroke, and combined vascular events within 1 year. Univariate and multivariate logistic or Cox regression analyses were used to investigate the association between FAR quartiles and adverse outcomes. 
Results: A total of 8984 patients with AIS were enrolled in this study. After one-year follow-up, 238 patients were lost to follow-up. A total of 1230(14.06%) patients had poor functional outcomes; 932(10.37%) and 981(10.92%) experienced stroke recurrence and combined vascular events, respectively. The adjusted odds ratios/hazard ratios and 95% confidence intervals of the highest quartile of the FAR(&gt;11.44) were 1.64(1.35-2.00) for poor functional outcomes, 1.68(1.34-2.10) for disability, 1.40(1.02-1.94) for all-cause death, 1.11(0.92-1.34) for stroke recurrence, and 1.11(0.92-1.33) for combined vascular event, respectively. 
Conclusion: High FAR(&gt;11.44) increased the risk of short- and long-term poor functional outcomes, including disability and all-cause death among patients with AIS. The FAR may play an important role in the early stratification of patients with AIS.
DOI: 10.6084/m9.figshare.24599202
title: Supplementary Material for: CT hyperdense lesions after endovascular therapy in acute ischemic stroke: imaging findings and clinical significance

description: Background The hyperdense lesion on non-contrast CT (NCCT) is a common postoperative phenomenon in acute ischemic stroke (AIS) patients who are treated with endovascular therapy (EVT). Both contrast extravasation and hemorrhagic transformation presented hyperdense lesions on NCCT, which are sometimes difficult to distinguish them. Summary of Review Radiographic findings are important for identifying contrast extravasation and hemorrhagic transformation. We recommended a standardized follow-up protocol involving imaging and clinical evaluation as it will allow neurologists and neuroradiologists to reveal the relationships between these hyperdensities and various clinical outcomes. Key Messages Dual-energy CT and susceptibility weighted imaging are capable of distinguishing contrast extravasation and hemorrhagic transformation at an early stage after EVT. However, in institutions without access to such technology, a follow-up protocol based on NCCT is crucial
DOI: 10.6084/m9.figshare.24799167
title: Supplementary Material for: Ethnic Differences in Carotid Intima Media Thickness and Plaque Presence - The HELIUS study

description: Introduction
In the Netherlands, the prevalence of cardiovascular diseases (CVD) is higher among South-Asian Surinamese and lower among Moroccans compared to the Dutch. Traditional risk factors for atherosclerotic CVD do not fully explain these disparities. We aim to assess ethnic differences in plaque presence and intima media thickness (cIMT) and explore to which extent these differences are explained by traditional risk factors.

Methods
We used cross-sectional data from a subgroup of participants enrolled in the multi-ethnic population-based HEalthy Life In an Urban Setting (HELIUS) study who underwent carotid ultrasonography. Logistic and linear regression models were built to assess ethnic differences in plaque presence and cIMT with the Dutch population as reference. Additional models were created to adjust for socioeconomic status, body height and cardiovascular risk factors.

Results
Of the 3022 participants, 1183, 1051 and 790 individuals were of Dutch, South-Asian Surinamese and Moroccan descent. Mean age was 60.9 years (SD 8.0), 52.8% was female. Compared to the Dutch, we found lower odds for plaque presence in Moroccans (0.77, 95% CI 0.62; 0.95) and no significant differences between the South-Asian Surinamese and Dutch population (0.91, 95% CI 0.76; 1.10). After adjustment for CVD risk factors, we found a lower plaque presence in South-Asian Surinamese (0.63, 95% CI 0.48; 0.82). In both Moroccan and South-Asian Surinamese individuals, adjustment for socioeconomic status did not materially change the results. cIMT was lower in South-Asian Surinamese compared to the Dutch (-17.9 µm, 95% CI -27.9; -7.9) and partly explained by ethnic differences in body height as South-Asian Surinamese individuals were, on average, shorter than the Dutch population. No differences in cIMT between Moroccans and Dutch were found.

Conclusions
cIMT and plaque prevalence differ between ethnic groups independent of CVD risk. Lower plaque prevalence in Moroccans was partly attributable to a lower prevalence of traditional CVD risk factors, while body height was an important contributor to differences in cIMT in South-Asians. This study emphasizes the need for ethnic-specific cut-off values for plaque presence and cIMT.
DOI: 10.6084/m9.figshare.27078091
title: Supplementary Material for: Receiving a pathogenic variant in a population breast cancer screening trial: a mixed method study

description: Introduction: Risk-based breast cancer screening aims to address persistent high morbidity and mortality. This study examines the experience of participants in the WISDOM (Women Informed to Screen Depending on Measures of Risk) trial who received a pathogenic variant in one of nine high or moderate penetrance breast cancer genes.
Methods: Participants completed a brief survey (n=181) immediately following results disclosure and one year later. Descriptive statistics were computed and comparisons between participants at different risk levels were performed using Fisher’s Exact and McNemar’s tests. Analysis of qualitative interviews (n=42) at 2-4 weeks and six months post results disclosure compared responses at the two timepoints, and explained and elaborated on the survey data.
Results: 66.3% of survey respondents felt very or moderately prepared to receive genomic results. At the T1 survey 80.7% of participants had shared the genetic result with a blood relative, increasing to 88.4% at T2; providing information and encouraging cascade testing were the most common reasons for sharing. Communication with a blood relative, other health care providers beyond the primary care provider, and cascade testing were higher for participants with a high risk than low or moderate risk genomic finding. Qualitative interviews elucidated varied reasons why participants felt (un)prepared for the results, including whether or not they had a family history of breast cancer, and illustrate the complexity of decision-making about sharing results.
Conclusions: Although most participants communicated results with family members and health care providers in accord with their risk level, questions remain about how to adequately prepare individuals to receive pathogenic results, ensure timely and accessible follow-up care, and facilitate genetic counseling and cascade testing of at-risk relatives in the setting of population risk-based screening.
DOI: 10.6084/m9.figshare.6741422.v18
title: COCI CSV dataset of all the citation data

description: This dataset contains all the citation data (in CSV format) included in COCI, released on 31 October 2022. In particular, each line of the CSV file defines a citation, and includes the following information: <strong>[field "oci"]</strong> the Open Citation Identifier (OCI) for the citation; <strong>[field "citing"]</strong> the DOI of the citing entity; <strong>[field "cited"]</strong> the DOI of the cited entity; <strong>[field "creation"]</strong> the creation date of the citation (i.e. the publication date of the citing entity); <strong>[field "timespan"]</strong> the time span of the citation (i.e. the interval between the publication date of the cited entity and the publication date of the citing entity); <strong>[field "journal_sc"]</strong> it records whether the citation is a journal self-citations (i.e. the citing and the cited entities are published in the same journal); <strong>[field "author_sc"]</strong> it records whether the citation is an author self-citation (i.e. the citing and the cited entities have at least one author in common).<br> This version of the dataset contains: 1,392,036,835 citations; 76,072,926 bibliographic resources. The size of the zipped archive is 35.5 GB, while the size of the unzipped CSV file is 226.5 GB. <br> Additional information about COCI can be retrieved in the <sub>official webpage</sub>.<br>
DOI: 10.1594/wdcc/cmip5.csa0pc
title: ACCESS1-0 model output prepared for CMIP5 piControl, served by ESGF

description: Project: IPCC Assessment Report 5 and Coupled Model Intercomparison Project data sets - These data belong to two projects: 1) to the Assessment Report No 5 of the International Panel on Climate Change (IPCC-AR5) and 2) to the Coupled Model Intercomparison Project No 5 (CMIP5). CMIP5 is executed by the Program for Climate Model Diagnosis and Intercomparison (PCMDI) on behalf of the World Climate Research Programme (WCRP). Most of the data is replicated between the three data nodes at the World Data Centre for Climate (WDCC), the British Atmospheric Data Centre (BADC), and the PCMDI. The project embraces the simulations with about 30 climate models of about 20 institutes worldwide. Summary: piControl is an experiment of the CMIP5 - Coupled Model Intercomparison Project Phase 5 ( https://pcmdi.llnl.gov/mips/cmip5 ). CMIP5 is meant to provide a framework for coordinated climate change experiments for the next five years and thus includes simulations for assessment in the AR5 as well as others that extend beyond the AR5. 3.1 piControl (3.1 Pre-Industrial Control) - Version 1: Pre-Industrial coupled atmosphere/ocean control run. Imposes non-evolving pre-industrial conditions. Experiment design: https://pcmdi.llnl.gov/mips/cmip5/experiment_design.html List of output variables: https://pcmdi.llnl.gov/mips/cmip5/datadescription.html Output: time series per variable in model grid spatial resolution in netCDF format Earth System model and the simulation information: CIM repository Entry name/title of data are specified according to the Data Reference Syntax ( https://pcmdi.llnl.gov/mips/cmip5/docs/cmip5_data_reference_syntax.pdf ) as activity/product/institute/model/experiment/frequency/modeling realm/MIP table/ensemble member/version number/variable name/CMOR filename.nc .
DOI: 10.1594/wdcc/cmip5.csa3pc
title: ACCESS1-3 model output prepared for CMIP5 piControl, served by ESGF

description: Project: IPCC Assessment Report 5 and Coupled Model Intercomparison Project data sets - These data belong to two projects: 1) to the Assessment Report No 5 of the International Panel on Climate Change (IPCC-AR5) and 2) to the Coupled Model Intercomparison Project No 5 (CMIP5). CMIP5 is executed by the Program for Climate Model Diagnosis and Intercomparison (PCMDI) on behalf of the World Climate Research Programme (WCRP). Most of the data is replicated between the three data nodes at the World Data Centre for Climate (WDCC), the British Atmospheric Data Centre (BADC), and the PCMDI. The project embraces the simulations with about 30 climate models of about 20 institutes worldwide. Summary: piControl is an experiment of the CMIP5 - Coupled Model Intercomparison Project Phase 5 ( https://pcmdi.llnl.gov/mips/cmip5 ). CMIP5 is meant to provide a framework for coordinated climate change experiments for the next five years and thus includes simulations for assessment in the AR5 as well as others that extend beyond the AR5. 3.1 piControl (3.1 Pre-Industrial Control) - Version 1: Pre-Industrial coupled atmosphere/ocean control run. Imposes non-evolving pre-industrial conditions. Experiment design: https://pcmdi.llnl.gov/mips/cmip5/experiment_design.html List of output variables: https://pcmdi.llnl.gov/mips/cmip5/datadescription.html Output: time series per variable in model grid spatial resolution in netCDF format Earth System model and the simulation information: CIM repository Entry name/title of data are specified according to the Data Reference Syntax ( https://pcmdi.llnl.gov/mips/cmip5/docs/cmip5_data_reference_syntax.pdf ) as activity/product/institute/model/experiment/frequency/modeling realm/MIP table/ensemble member/version number/variable name/CMOR filename.nc .
DOI: 10.5281/zenodo.10818626
title: Data from "Three-dimensional wave breaking"
DOI: 10.5281/zenodo.11481313
title: A hot-emitter transistor based on stimulated emission of heated carriers

description: Relevant data for "A hot-emitter transistor based on stimulated emission of heated carriers".
DOI: 10.6084/m9.figshare.21334422.v1
title: Akkermansia muciniphila protects mice against an emerging tick-borne viral pathogen

description: The dataset contains the all source data of this manuscript.
DOI: 10.6084/m9.figshare.24511456
title: Supplementary Material for: Radiographic signs of advanced cerebral venous thrombosis negatively modulate the effectiveness of endovascular treatments

description: Introduction: Endovascular treatment (EVT) is a therapeutic option for cerebral venous thrombosis (CVT); however, its benefit over conservative medical management has not been proven. Whether current patient selection practices are appropriate for EVT is unclear. Methods: This was a nationwide study of the 2016-2020 National Inpatient Sample database. Adult CVT patients and EVT treatments were identified. Patient demographics, medical comorbidities, CVT risk factors, and CVT manifestations were identified. Presence of radiographic signs of advanced and severe CVT (venous infarction, cerebral edema, and intracranial hemorrhage) were recorded. Primary and secondary outcomes were good discharge outcomes and in-hospital mortality, respectively. Results: 17,130 CVT patients were identified, and 56.7% had good discharge outcomes while 4.6% died during hospitalization. 945 (5.5%) received EVT, and EVT patients were more likely to have cerebral infarction (35.4% vs. 21.8%, p&lt;0.001), edema (35.4% vs. 20.1%, p&lt;0.001), and hemorrhage (37.6% vs. 19.7%, p&lt;0.001). After multivariable adjustments, EVT for patients without infarction, edema, or hemorrhage was moderately associated with higher odds of good outcomes (OR 1.86 [95%CI 0.98 - 3.53], p=0.059) and resulted in zero deaths. However, with increasing burden of radiographic signs of advanced CVT measured by the cumulative presence of infraction, edema, and hemorrhage, EVT was associated with decreasing odds of good outcomes and increasing odds of in-hospital mortality compared to medical management (interaction p=0.046 and 0.029, respectively). Conclusions: EVT may lead to higher rates of favorable hospitalization outcomes in patients who have not yet developed overt parenchymal manifestations of backpressure changes; presence of infarction, edema, and hemorrhage may diminish the short-term effectiveness of EVT.